VIGL Insider Trading (Vigil Neuroscience)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $106,793.52
Insider Selling (Last 12 Months): $0.00
Vigil Neuroscience Share Price & Price History
Current Price: $2.56
Price Change: ▼ Price Decrease of -0.1 (-3.76%)
As of 05/19/2022 01:00 AM ET
Last Century's Oil Boom Repeats Today With Lithium?
The budding lithium industry looks similar to early days of the oil boom. In fact, lithium has been called the "new oil." As internal combustion engines give way to lithium-filled electric vehicle batteries, demand for the metal is skyrocketing. The U.S. is desperate for more domestic sources of lithium, and geologists are pointing to Nevada.
See Why Nevada Lithium Opportunity Looks Promising
Vigil Neuroscience Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/16/2022||Clay Thorp||Director||Buy||21,802||$2.76||$60,173.52||1,541,137|| |
|5/5/2022||Evan Thackaberry||SVP||Buy||1,500||$4.00||$6,000.00||1,500|| |
|5/3/2022||Christopher Verni||General Counsel||Buy||4,000||$3.77||$15,080.00||4,000|| |
|5/3/2022||Ivana Magovcevic-Liebisch||CEO||Buy||1,000||$3.94||$3,940.00||203,687|| |
|3/28/2022||Clay Thorp||Director||Buy||3,000||$7.20||$21,600.00|| |
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Vigil Neuroscience Institutional Trading History
Data available starting January 2016
|Reporting Date||Hedge Fund||Shares Held||Market Value||% of Portfolio||Quarterly Change in Shares||Ownership in Company||Details|
|5/17/2022||Point72 Hong Kong Ltd||12,667||$89K||0.0%||N/A||0.045%|
|5/17/2022||Rock Springs Capital Management LP||471,958||$3.32M||0.1%||N/A||1.669%|
|5/16/2022||Goldman Sachs Group Inc.||73,839||$0.52M||0.0%||N/A||0.261%|
|5/16/2022||Deep Track Capital LP||389,141||$2.74M||0.2%||N/A||1.377%|
|5/16/2022||State Street Corp||54,479||$0.38M||0.0%||N/A||0.193%|
|5/13/2022||Renaissance Technologies LLC||20,041||$0.14M||0.0%||N/A||0.071%|
|5/13/2022||Northern Trust Corp||56,683||$0.40M||0.0%||N/A||0.201%|
|5/13/2022||Charles Schwab Investment Management Inc.||19,198||$0.14M||0.0%||N/A||0.068%|
|5/13/2022||Vanguard Group Inc.||385,198||$2.71M||0.0%||N/A||1.363%|
|5/12/2022||Artal Group S.A.||1,121,191||$7.88M||0.3%||N/A||3.966%|
|5/11/2022||Bank of New York Mellon Corp||13,341||$94K||0.0%||N/A||0.047%|
|5/5/2022||New York State Common Retirement Fund||8,500||$60K||0.0%||N/A||0.030%|
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Vigil Neuroscience?
Who are the major institutional investors of Vigil Neuroscience?
Which major investors are buying Vigil Neuroscience stock?
During the previous quarter, VIGL stock was acquired by institutional investors including:
- Artal Group S.A.
- Rock Springs Capital Management LP
- Deep Track Capital LP
- Vanguard Group Inc.
- BlackRock Inc.
- Goldman Sachs Group Inc.
- Citigroup Inc.
- Northern Trust Corp
During the previous year, these company insiders have bought Vigil Neuroscience stock:
Learn More investors buying Vigil Neuroscience stock.
- Clay Thorp (Director)
- Ivana Magovcevic-Liebisch (CEO)
- Christopher Verni (General Counsel)
- Evan Thackaberry (SVP)